Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. filed this Form 8-K regarding a material revenue interest financing agreement entered into on May 3, 2022. The company is developing vonoprazan, including for erosive esophagitis (EE) and other gastrointestinal indications. The filing does not provide quarterly operating results or a specific financial reporting period.
Key Financial Terms and Liquidity
- The company will receive up to $260 million from NovaQuest Capital Management-affiliated entities, Sagard Holdings Manager LP, and Hercules Capital, Inc.
- $100 million was to be funded at the initial closing, by May 17, 2022.
- An additional $160 million would become available upon FDA approval of vonoprazan for EE on or before March 31, 2024.
- The company may pursue up to $15 million of additional funding tied to FDA approval for EE and up to $25 million tied to a sales milestone, subject to specified timing and third-party commitment requirements. The initial investors have a right of first offer for these additional financings.
- Investors are entitled to a royalty initially equal to 10% of net sales of products containing vonoprazan. The rate may step down above specified annual sales thresholds and if vonoprazan receives approval for symptomatic non-erosive gastroesophageal reflux disease.
- Royalty payments terminate after investors receive aggregate payments equal to 200% of the Investment Amount.
- After the earlier of April 30, 2024 or payment of the EE approval funding, the company may terminate the arrangement by paying the remaining amount required to reach 200% of the Investment Amount.
- If investors have not received at least 100% of the Investment Amount by December 31, 2028, or 200% by December 31, 2037, the company must make cash payments sufficient to reach the applicable minimum amount.
The filing does not provide revenue, net income, cash flow, margins, cash balances, total debt, or liquidity runway. The financing creates a direct financial obligation and is secured within the company’s broader financing arrangements, subject to the related loan amendment.
Material Changes Versus the Prior Comparable Period
- The company entered into a new revenue interest financing arrangement providing an initial $100 million of funding and potential total funding of up to $260 million, plus possible additional financings.
- The company amended its September 17, 2021 Loan and Security Agreement to permit the revenue interest financing and related transactions.
- The financing adds future royalty and potential minimum-payment obligations tied to vonoprazan sales, regulatory milestones, defaults, and changes of control.
Guidance, Outlook, Risks, and Unusual Items
- The additional $160 million is contingent on FDA approval of vonoprazan for EE by March 31, 2024; the filing provides no assurance that approval will occur.
- Future obligations depend on vonoprazan commercial sales, regulatory outcomes, sales milestones, and the amount ultimately funded.
- Events of default or a change of control may trigger additional payments to investors.
- The agreement may reduce future cash flows from vonoprazan sales because of the royalty obligation and may require substantial cash payments if specified minimum returns are not achieved.
- The filing states that the descriptions of the financing agreement and loan amendment are summaries and are qualified by the complete agreements, which the company intended to file with its Form 10-Q for the quarter ending June 30, 2022.
Important Facts for Investors to Verify
- Whether the initial $100 million was funded by May 17, 2022 and the amount ultimately drawn.
- Whether FDA approval for vonoprazan for EE was obtained by March 31, 2024 and whether the additional $160 million became available.
- The final Investment Amount, including any subsequent financings, and the applicable royalty step-down thresholds.
- The complete revenue interest financing agreement, loan amendment, security terms, default provisions, and change-of-control payment requirements.
- The company’s cash balance, operating cash burn, existing debt, and liquidity runway in subsequent periodic filings.